Richard A. Sherer

Physicians' Primary Care of SWFL


APA and Pharma-Funded CME Part Ways

May 27, 2009

Following the recommendations of a working group set up to examine the American Psychiatric Association’s (APA) relationship with the pharmaceutical industry, the Board of Trustees has voted to phase out industry-sponsored educational programs and industry-supplied meals at annual meetings and educational symposia.

Update on Conflicts of Interest Allegations

March 05, 2009

Two prominent psychiatrists have agreed to curtail their research activities following revelations about sizable consulting fees from pharmaceutical manufacturers.

Antipsychotics in Dementia: Evidence of Risk Mounts

October 01, 2008

The use of antipsychotics to quiet agitated older adults with dementia has come under increasing fire. After a Canadian study demonstrated an increased risk of adverse events or death with these agents,1 the FDA expanded its earlier warning to physicians.

Personality Disorder: “Untreatable” Myth Is Challenged

July 02, 2008

Success with new approaches to the psychotherapeutic treatment of borderline personality disorder (BPD) and other DSM-IV personality disorders has been reported in several studies recently, raising hopes that an intractable set of illnesses may not be as hopeless as once thought.

Violence Against Mental Health Professionals: Fenton Death Highlights Concerns

January 01, 2007

Once his colleagues began to recover from the shock, the death of Dr Wayne S. Fenton triggered a discussion in the professional and lay press about the risks of violence to mental health professionals posed by mentally ill patients. Fenton was found unconscious and bleeding in his office in Bethesda, Md, on Sunday, September 3, 2006. He had been beaten severely around the head and died at the scene.

British Study: Older Antipsychotics Just as Good

December 01, 2006

A new study comparing the benefits of second-generation antipsychotics (SGAs) with their older counterparts in patients with schizophrenia has yielded a surprising result. The study, funded by the UK National Health Service, found that the overall differences between first- and second-generation antipsychotics did not reach statistical significance.